Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview

12 Jun 2015

Abstract excerpt

Myeloproliferative neoplasms are caused by a clonal proliferation of a hematopoietic progenitor. First described in 1951 as 'Myeloproliferative Diseases' and reevaluated by the World Health Organization classification system in 2011, myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis in a subgroup called breakpoint cluster region-Abelson fusion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Kruppel-like factors research
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26408371
DOI: 10.1016/j.bjhh.2014.10.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overviewPMID 26408371Read ↗

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.Semantic proximity Read ↗

Jak-2 positive myeloproliferative neoplasms.Semantic proximity Read ↗

The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.Semantic proximity Read ↗

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.Semantic proximity Read ↗

[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?]Semantic proximity Read ↗

The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasmsSemantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Myeloproliferative disordersSemantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasmsSemantic proximity Read ↗

The spectrum of JAK2-positive myeloproliferative neoplasms.Semantic proximity Read ↗

[Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.